Insight, China's Pharmaceutical Industry

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026

China’s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations...

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) announced a definitive agreement to acquire Organon & Co....

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026

AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has granted approvals...

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Fineline Cube Apr 24, 2026

Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection...

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026

Star Sports Medicine Co., Ltd., a Chinese sports medical device manufacturer, successfully completed its initial...

Company Medical Device

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Fineline Cube Apr 24, 2026

Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China’s National...

Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026

Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun...

Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026

China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration...

Company Drug

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Fineline Cube Apr 24, 2026

AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete...

Company Drug

Regeneron Secures FDA Approval for Otarmeni Gene Therapy and Announces Landmark U.S. Pricing Agreement

Fineline Cube Apr 24, 2026

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has...

Company

Thermo Fisher Scientific Reports 6% Revenue Growth in Q1 2026 Driven by Innovative Product Launches and Strategic AI Collaboration

Fineline Cube Apr 24, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced first-quarter 2026 financial results with revenue growing 6%...

Others

China’s National Health Commission Proposes Sweeping Reforms to Narcotics and Psychotropic Drugs Management Framework

Fineline Cube Apr 24, 2026

China’s National Health Commission (NHC) released a draft notification for public consultation on comprehensive revisions...

Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026

SciClone Pharmaceuticals Inc (HKG: 6600) announced a strategic partnership agreement with JD Healthcare (HKG: 6618),...

Company

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds

Fineline Cube Apr 24, 2026

Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion...

Company Drug

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Fineline Cube Apr 23, 2026

Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate...

Company Drug

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Fineline Cube Apr 23, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) has withdrawn its New Drug Application (NDA) for rademikibart...

Company

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Fineline Cube Apr 23, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026...

Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026

Sipai Health Technology Co., Ltd. (HKG: 0314), also known as Mebanks, has announced the sale...

Company Drug

Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells

Fineline Cube Apr 23, 2026

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has announced the initiation of a single-center,...

Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026

AbbVie (NYSE: ABBV) has announced plans to invest $1.4 billion to construct a state-of-the-art pharmaceutical...

Insight, China's Pharmaceutical Industry

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested

Regeneron Secures FDA Approval for Otarmeni Gene Therapy and Announces Landmark U.S. Pricing Agreement

Thermo Fisher Scientific Reports 6% Revenue Growth in Q1 2026 Driven by Innovative Product Launches and Strategic AI Collaboration

China’s National Health Commission Proposes Sweeping Reforms to Narcotics and Psychotropic Drugs Management Framework

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds

Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026

Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month

Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

You Missed

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial